CSI Market
Sign In | Register

Bridgebio Oncology Therapeutics Inc (BBOT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BBOT Annual Cash Flow →
Reviewing cash flow figures over time highlights how Bridgebio Oncology Therapeutics Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-98.56
Depreciation & amortization0.15
Amortization of Other Assets0.23
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation11.10
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Of Common Stock Issuable To Related Party-
Change In Fair Value Of Participation Right Liability-
Net Accretion Of Premiums On Marketable Securities-
Finance Lease Right Of Use Asset Amortization-
Increase Decrease Accrued Research And Development Liabilities-
Increase Decrease In Professional Fee Payable0.88
Adjustments To Additional Paid In Capital Mark To Market-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-1.54
Increase (Decrease) in Accounts Payable5.36
Accrued Expense10.85
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense9.46
Other Working Capital0.23
Other Noncash Income (Expense)0.00
Other net-0.33
Payments for (Proceeds from) Other Operating Activities-17.21
Discontinued operations0.00
Net Cash flow from Operating Activities-80.28
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities79.58
Payments to Acquire Marketable Securities-319.18
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-239.68
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.12
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock112.75
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-112.54
Payment Of Deferred Transaction Costs-
Issuance Of Series B Redeemable Convertible Preferred Stock Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.33
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-80.35
Total Cash Flow-319.62
4 historic quarters locked

Sign in to unlock the full Bridgebio Oncology Therapeutics Inc cash flow history.

Sign In Create Free Account

About Bridgebio Oncology Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-344661

Figures are derived from filed reports and may be restated. Historical data is subject to revision.